Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W F Symmans

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Cancer|May 4, 2000
Invasive carcinoma in clinically suspicious breast masses diagnosed as adenocarcinoma by fine-needle aspirationD C Chhieng, G Fernandez, J F Cangiarella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2013
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus StatementH A Azim, S Michiels, F Zagouri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 26, 2008
Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacyM Zoubir, M C Mathieu, C Mazouni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2014
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapyA Sheri, I E Smith, S R Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatmentW F Symmans, M D Volm, R L Shapiro, et al.
British Journal of Cancer|February 21, 2012
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypesB Dutta, L Pusztai, Y Qi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 1, 2008
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumabF Peintinger, A U Buzdar, H M Kuerer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 15, 2009
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancerC Liedtke, K Broglio, S Moulder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2007
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancersC Mazouni, S-W Kau, D Frye, et al.
ESMO Open|February 11, 2026
Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancerA Grinshpun, D Dustin, M Cai, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Cancer|May 4, 2000
Invasive carcinoma in clinically suspicious breast masses diagnosed as adenocarcinoma by fine-needle aspirationD C Chhieng, G Fernandez, J F Cangiarella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2013
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus StatementH A Azim, S Michiels, F Zagouri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 26, 2008
Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacyM Zoubir, M C Mathieu, C Mazouni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2014
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapyA Sheri, I E Smith, S R Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatmentW F Symmans, M D Volm, R L Shapiro, et al.
British Journal of Cancer|February 21, 2012
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypesB Dutta, L Pusztai, Y Qi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 1, 2008
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumabF Peintinger, A U Buzdar, H M Kuerer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 15, 2009
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancerC Liedtke, K Broglio, S Moulder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2007
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancersC Mazouni, S-W Kau, D Frye, et al.
ESMO Open|February 11, 2026
Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancerA Grinshpun, D Dustin, M Cai, et al.
Pageof 6